Clinical Report: Genetic Testing in Retinoblastoma: New Applications
Overview
Recent advancements in genetic testing for retinoblastoma have expanded its role in diagnosis and prognosis, particularly through liquid biopsy and molecular profiling.
Background
Retinoblastoma, a pediatric eye cancer, can manifest in heritable and nonheritable forms, necessitating accurate genetic testing. Understanding the genetic underpinnings is crucial for ophthalmologists to counsel families and identify at-risk children.
Data Highlights
No numerical data available.
Key Findings
Liquid biopsy and molecular profiling are enhancing the diagnostic capabilities for retinoblastoma.
Aqueous humor liquid biopsy demonstrated a feasibility rate of 98% and sensitivity of 98% for detecting active disease.
Circulating tumor DNA (ctDNA) can be detected in up to 85% of patients with untreated unilateral retinoblastoma.
Genomic analysis of aqueous humor cfDNA accurately reflects somatic copy number alterations present in tumors.
False-negative results may occur in small tumors or those retaining an intact RB1 gene.
Clinical Implications
Ophthalmologists should consider the integration of liquid biopsy techniques in the diagnostic process for retinoblastoma.
Conclusion
Advancements in genetic testing, particularly through liquid biopsy, provide tools for the diagnosis and management of retinoblastoma.
A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors